Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2003 May;58(5):447–452. doi: 10.1136/thorax.58.5.447

Lung cancer • 5: State of the art radiotherapy for lung cancer

A Price 1
PMCID: PMC1746685  PMID: 12728171

Full Text

The Full Text of this article is available as a PDF (123.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abratt R. P., Willcox P. A. Changes in lung function and perfusion after irradiation in patients with lung cancer. Lung Cancer. 1994 Jul;11(1-2):61–69. doi: 10.1016/0169-5002(94)90283-6. [DOI] [PubMed] [Google Scholar]
  2. Aupérin A., Arriagada R., Pignon J. P., Le Péchoux C., Gregor A., Stephens R. J., Kristjansen P. E., Johnson B. E., Ueoka H., Wagner H. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999 Aug 12;341(7):476–484. doi: 10.1056/NEJM199908123410703. [DOI] [PubMed] [Google Scholar]
  3. Ball D., Bishop J., Smith J., O'Brien P., Davis S., Ryan G., Olver I., Toner G., Walker Q., Joseph D. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol. 1999 Aug;52(2):129–136. doi: 10.1016/s0167-8140(99)00093-6. [DOI] [PubMed] [Google Scholar]
  4. Barnes E. A., Murray B. R., Robinson D. M., Underwood L. J., Hanson J., Roa W. H. Dosimetric evaluation of lung tumor immobilization using breath hold at deep inspiration. Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1091–1098. doi: 10.1016/s0360-3016(01)01592-9. [DOI] [PubMed] [Google Scholar]
  5. Blanke C., Ansari R., Mantravadi R., Gonin R., Tokars R., Fisher W., Pennington K., O'Connor T., Rynard S., Miller M. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol. 1995 Jun;13(6):1425–1429. doi: 10.1200/JCO.1995.13.6.1425. [DOI] [PubMed] [Google Scholar]
  6. Bremnes R. M., Sundstrøm S., Vilsvik J., Aasebø U., Norwegian Lung Cancer Study Group Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J Clin Oncol. 2001 Aug 1;19(15):3532–3538. doi: 10.1200/JCO.2001.19.15.3532. [DOI] [PubMed] [Google Scholar]
  7. Brown J. M. Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):319–326. doi: 10.1016/s0360-3016(00)01482-6. [DOI] [PubMed] [Google Scholar]
  8. Byhardt R. W., Scott C., Sause W. T., Emami B., Komaki R., Fisher B., Lee J. S., Lawton C. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):469–478. doi: 10.1016/s0360-3016(98)00251-x. [DOI] [PubMed] [Google Scholar]
  9. Choi N. C., Herndon J. E., 2nd, Rosenman J., Carey R. W., Chung C. T., Bernard S., Leone L., Seagren S., Green M. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 1998 Nov;16(11):3528–3536. doi: 10.1200/JCO.1998.16.11.3528. [DOI] [PubMed] [Google Scholar]
  10. Choi N. C., Kanarek D. J. Toxicity of thoracic radiotherapy on pulmonary function in lung cancer. Lung Cancer. 1994 Mar;10 (Suppl 1):S219–S230. doi: 10.1016/0169-5002(94)91685-3. [DOI] [PubMed] [Google Scholar]
  11. Clamon G., Herndon J., Cooper R., Chang A. Y., Rosenman J., Green M. R. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol. 1999 Jan;17(1):4–11. doi: 10.1200/JCO.1999.17.1.4. [DOI] [PubMed] [Google Scholar]
  12. Cox G., Walker R. A., Andi A., Steward W. P., O'Byrne K. J. Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer. 2000 Sep;29(3):169–177. doi: 10.1016/s0169-5002(00)00124-0. [DOI] [PubMed] [Google Scholar]
  13. Cullen M. H., Billingham L. J., Woodroffe C. M., Chetiyawardana A. D., Gower N. H., Joshi R., Ferry D. R., Rudd R. M., Spiro S. G., Cook J. E. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999 Oct;17(10):3188–3194. doi: 10.1200/JCO.1999.17.10.3188. [DOI] [PubMed] [Google Scholar]
  14. De Ruysscher D., Vansteenkiste J. Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects. Radiother Oncol. 2000 Apr;55(1):1–9. doi: 10.1016/s0167-8140(00)00156-0. [DOI] [PubMed] [Google Scholar]
  15. Depierre Alain, Milleron Bernard, Moro-Sibilot Denis, Chevret Sylvie, Quoix Elisabeth, Lebeau Bernard, Braun Denis, Breton Jean-Luc, Lemarié Etienne, Gouva Sylvie. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002 Jan 1;20(1):247–253. doi: 10.1200/JCO.2002.20.1.247. [DOI] [PubMed] [Google Scholar]
  16. Devereux S., Hatton M. Q., Macbeth F. R. Immediate side effects of large fraction radiotherapy. Clin Oncol (R Coll Radiol) 1997;9(2):96–99. doi: 10.1016/s0936-6555(05)80447-9. [DOI] [PubMed] [Google Scholar]
  17. Erdi Yusuf E., Rosenzweig Kenneth, Erdi Alev K., Macapinlac Homer A., Hu Yu Chi, Braban Louise E., Humm John L., Squire Olivia D., Chui Chen Shou, Larson Steven M. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol. 2002 Jan;62(1):51–60. doi: 10.1016/s0167-8140(01)00470-4. [DOI] [PubMed] [Google Scholar]
  18. Erridge Sara C., Thomson Catherine S., Davidson Joyce, Jones Richard D., Price Allan, Scottish Cancer Trials Lung Group and The Scottish Cancer Therapy Network Factors influencing the use of thoracic radiotherapy in lung cancer--an analysis of the 1995 Scottish lung cancer audit. Clin Oncol (R Coll Radiol) 2002 Jun;14(3):219–227. doi: 10.1053/clon.2001.0046. [DOI] [PubMed] [Google Scholar]
  19. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., Katagami N., Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999 Sep;17(9):2692–2699. doi: 10.1200/JCO.1999.17.9.2692. [DOI] [PubMed] [Google Scholar]
  20. Graham M. V., Purdy J. A., Emami B., Harms W., Bosch W., Lockett M. A., Perez C. A. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):323–329. doi: 10.1016/s0360-3016(99)00183-2. [DOI] [PubMed] [Google Scholar]
  21. Gregor A. Gemcitabine plus radiotherapy for non-small cell lung cancer. Semin Oncol. 1997 Jun;24(3 Suppl 8):S8–39-S8-41. [PubMed] [Google Scholar]
  22. Hayman J. A., Martel M. K., Ten Haken R. K., Normolle D. P., Todd R. F., 3rd, Littles J. F., Sullivan M. A., Possert P. W., Turrisi A. T., Lichter A. S. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol. 2001 Jan 1;19(1):127–136. doi: 10.1200/JCO.2001.19.1.127. [DOI] [PubMed] [Google Scholar]
  23. Hernandez P., Gursahaney A., Roman T., Schwartzman K., Donath D., Cosio M. G., Levy R. D. High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation. Thorax. 1996 Apr;51(4):354–358. doi: 10.1136/thx.51.4.354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Herridge Margaret S., Cheung Angela M., Tansey Catherine M., Matte-Martyn Andrea, Diaz-Granados Natalia, Al-Saidi Fatma, Cooper Andrew B., Guest Cameron B., Mazer C. David, Mehta Sangeeta. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003 Feb 20;348(8):683–693. doi: 10.1056/NEJMoa022450. [DOI] [PubMed] [Google Scholar]
  25. Hirota S., Tsujino K., Endo M., Kotani Y., Satouchi M., Kado T., Hishikawa Y., Obayashi K., Takada Y., Kono M. Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy. Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):291–295. doi: 10.1016/s0360-3016(01)01648-0. [DOI] [PubMed] [Google Scholar]
  26. Huber R. M., Fischer R., Hautmann H., Pöllinger B., Häussinger K., Wendt T. Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):533–540. doi: 10.1016/s0360-3016(97)00008-4. [DOI] [PubMed] [Google Scholar]
  27. Jeremic B., Shibamoto Y., Acimovic L., Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 1995 Feb;13(2):452–458. doi: 10.1200/JCO.1995.13.2.452. [DOI] [PubMed] [Google Scholar]
  28. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 1996 Apr;14(4):1065–1070. doi: 10.1200/JCO.1996.14.4.1065. [DOI] [PubMed] [Google Scholar]
  29. Jeremic B., Shibamoto Y., Nikolic N., Milicic B., Milisavljevic S., Dagovic A., Aleksandrovic J., Radosavljevic-Asic G. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. J Clin Oncol. 1999 Jul;17(7):2092–2099. doi: 10.1200/JCO.1999.17.7.2092. [DOI] [PubMed] [Google Scholar]
  30. Kaasa S., Thorud E., Høst H., Lien H. H., Lund E., Sjølie I. A randomized study evaluating radiotherapy versus chemotherapy in patients with inoperable non-small cell lung cancer. Radiother Oncol. 1988 Jan;11(1):7–13. doi: 10.1016/0167-8140(88)90041-2. [DOI] [PubMed] [Google Scholar]
  31. Krol A. D., Aussems P., Noordijk E. M., Hermans J., Leer J. W. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation? Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):297–302. doi: 10.1016/0360-3016(95)00227-8. [DOI] [PubMed] [Google Scholar]
  32. Kubo H. D., Len P. M., Minohara S., Mostafavi H. Breathing-synchronized radiotherapy program at the University of California Davis Cancer Center. Med Phys. 2000 Feb;27(2):346–353. doi: 10.1118/1.598837. [DOI] [PubMed] [Google Scholar]
  33. Kwa S. L., Lebesque J. V., Theuws J. C., Marks L. B., Munley M. T., Bentel G., Oetzel D., Spahn U., Graham M. V., Drzymala R. E. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):1–9. doi: 10.1016/s0360-3016(98)00196-5. [DOI] [PubMed] [Google Scholar]
  34. Langendijk H., de Jong J., Tjwa M., Muller M., ten Velde G., Aaronson N., Lamers R., Slotman B., Wouters M. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiother Oncol. 2001 Mar;58(3):257–268. doi: 10.1016/s0167-8140(00)00345-5. [DOI] [PubMed] [Google Scholar]
  35. Langendijk J. A., Aaronson N. K., de Jong J. M., ten Velde G. P., Muller M. J., Lamers R. J., Slotman B. J., Wouters E. F. Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2001 Apr 15;19(8):2123–2133. doi: 10.1200/JCO.2001.19.8.2123. [DOI] [PubMed] [Google Scholar]
  36. Langendijk J. A., ten Velde G. P., Aaronson N. K., de Jong J. M., Muller M. J., Wouters E. F. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):149–155. doi: 10.1016/s0360-3016(99)00540-4. [DOI] [PubMed] [Google Scholar]
  37. Lupattelli M., Maranzano E., Bellavita R., Chionne F., Darwish S., Piro F., Latini P. Short-course palliative radiotherapy in non-small-cell lung cancer: results of a prospective study. Am J Clin Oncol. 2000 Feb;23(1):89–93. doi: 10.1097/00000421-200002000-00024. [DOI] [PubMed] [Google Scholar]
  38. Mac Manus Michael P., Wong Kevin, Hicks Rodney J., Matthews Jane P., Wirth Andrew, Ball David L. Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):351–361. doi: 10.1016/s0360-3016(01)02673-6. [DOI] [PubMed] [Google Scholar]
  39. Machtay M., Lee J. H., Shrager J. B., Kaiser L. R., Glatstein E. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol. 2001 Oct 1;19(19):3912–3917. doi: 10.1200/JCO.2001.19.19.3912. [DOI] [PubMed] [Google Scholar]
  40. Maguire P. D., Marks L. B., Sibley G. S., Herndon J. E., 2nd, Clough R. W., Light K. L., Hernando M. L., Antoine P. A., Anscher M. S. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. J Clin Oncol. 2001 Feb 1;19(3):705–711. doi: 10.1200/JCO.2001.19.3.705. [DOI] [PubMed] [Google Scholar]
  41. Maguire P. D., Sibley G. S., Zhou S. M., Jamieson T. A., Light K. L., Antoine P. A., Herndon J. E., 2nd, Anscher M. S., Marks L. B. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):97–103. doi: 10.1016/s0360-3016(99)00163-7. [DOI] [PubMed] [Google Scholar]
  42. Mayer R., Smolle-Juettner F. M., Szolar D., Stuecklschweiger G. F., Quehenberger F., Friehs G., Hackl A. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest. 1997 Oct;112(4):954–959. doi: 10.1378/chest.112.4.954. [DOI] [PubMed] [Google Scholar]
  43. Mehta M., Scrimger R., Mackie R., Paliwal B., Chappell R., Fowler J. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):23–33. doi: 10.1016/s0360-3016(00)01374-2. [DOI] [PubMed] [Google Scholar]
  44. Murray N., Coy P., Pater J. L., Hodson I., Arnold A., Zee B. C., Payne D., Kostashuk E. C., Evans W. K., Dixon P. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993 Feb;11(2):336–344. doi: 10.1200/JCO.1993.11.2.336. [DOI] [PubMed] [Google Scholar]
  45. Ohe Y., Yamamoto S., Suzuki K., Hojo F., Kakinuma R., Matsumoto T., Ohmatsu H., Nishiwaki Y. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer. 2001 Jan;37(1):54–63. doi: 10.1016/s0959-8049(00)00350-6. [DOI] [PubMed] [Google Scholar]
  46. Perez C. A., Pajak T. F., Rubin P., Simpson J. R., Mohiuddin M., Brady L. W., Perez-Tamayo R., Rotman M. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987 Jun 1;59(11):1874–1881. doi: 10.1002/1097-0142(19870601)59:11<1874::aid-cncr2820591106>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  47. Pignon J. P., Arriagada R., Ihde D. C., Johnson D. H., Perry M. C., Souhami R. L., Brodin O., Joss R. A., Kies M. S., Lebeau B. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992 Dec 3;327(23):1618–1624. doi: 10.1056/NEJM199212033272302. [DOI] [PubMed] [Google Scholar]
  48. Robnett T. J., Machtay M., Vines E. F., McKenna M. G., Algazy K. M., McKenna W. G. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):89–94. doi: 10.1016/s0360-3016(00)00648-9. [DOI] [PubMed] [Google Scholar]
  49. Rosenzweig K. E., Hanley J., Mah D., Mageras G., Hunt M., Toner S., Burman C., Ling C. C., Mychalczak B., Fuks Z. The deep inspiration breath-hold technique in the treatment of inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):81–87. doi: 10.1016/s0360-3016(00)00583-6. [DOI] [PubMed] [Google Scholar]
  50. Rosenzweig K. E., Mychalczak B., Fuks Z., Hanley J., Burman C., Ling C. C., Armstrong J., Ginsberg R., Kris M. G., Raben A. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer J. 2000 Mar-Apr;6(2):82–87. [PubMed] [Google Scholar]
  51. Samson M. J., van Sörnsen de Koste J. R., de Boer H. C., Tankink H., Verstraate M., Essers M., Visser A. G., Senan S. An analysis of anatomic landmark mobility and setup deviations in radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):827–832. doi: 10.1016/s0360-3016(98)00467-2. [DOI] [PubMed] [Google Scholar]
  52. Saunders M. I., Rojas A., Lyn B. E., Pigott K., Powell M., Goodchild K., Hoskin P. J., Phillips H., Verma N. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer. Br J Cancer. 1998 Nov;78(10):1323–1328. doi: 10.1038/bjc.1998.678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Saunders M., Dische S., Barrett A., Harvey A., Gibson D., Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet. 1997 Jul 19;350(9072):161–165. doi: 10.1016/s0140-6736(97)06305-8. [DOI] [PubMed] [Google Scholar]
  54. Sause W., Kolesar P., Taylor S I. V., Johnson D., Livingston R., Komaki R., Emami B., Curran W., Jr, Byhardt R., Dar A. R. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000 Feb;117(2):358–364. doi: 10.1378/chest.117.2.358. [DOI] [PubMed] [Google Scholar]
  55. Schaafsma J., Coy P. The effect of radiotherapy on the survival of non-small cell lung cancer patients. Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):291–298. doi: 10.1016/s0360-3016(98)00055-8. [DOI] [PubMed] [Google Scholar]
  56. Schaake-Koning C., van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., Kirkpatrick A., Koolen M., Maat B., Nijs A. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992 Feb 20;326(8):524–530. doi: 10.1056/NEJM199202203260805. [DOI] [PubMed] [Google Scholar]
  57. Shirato H., Shimizu S., Kunieda T., Kitamura K., van Herk M., Kagei K., Nishioka T., Hashimoto S., Fujita K., Aoyama H. Physical aspects of a real-time tumor-tracking system for gated radiotherapy. Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1187–1195. doi: 10.1016/s0360-3016(00)00748-3. [DOI] [PubMed] [Google Scholar]
  58. Sloan Jeff A., Bonner James A., Hillman Shauna L., Allmer Cristine, Shanahan Thomas G., Brooks Burke J., Marks Randolph S., Vargas-Chanes Delfino, Jett James R. A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1). Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):371–381. doi: 10.1016/s0360-3016(01)01819-3. [DOI] [PubMed] [Google Scholar]
  59. Stout R., Barber P., Burt P., Hopwood P., Swindell R., Hodgetts J., Lomax L. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Radiother Oncol. 2000 Sep;56(3):323–327. doi: 10.1016/s0167-8140(00)00252-8. [DOI] [PubMed] [Google Scholar]
  60. Stuschke M., Thames H. D. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):259–267. doi: 10.1016/s0360-3016(96)00511-1. [DOI] [PubMed] [Google Scholar]
  61. Suwinski R., Lee S. P., Withers H. R. Dose-response relationship for prophylactic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):797–806. doi: 10.1016/s0360-3016(97)00856-0. [DOI] [PubMed] [Google Scholar]
  62. Trovó M. G., Minatel E., Franchin G., Boccieri M. G., Nascimben O., Bolzicco G., Pizzi G., Torretta A., Veronesi A., Gobitti C. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1992;24(1):11–15. doi: 10.1016/0360-3016(92)91014-e. [DOI] [PubMed] [Google Scholar]
  63. Turrisi A. T., 3rd, Kim K., Blum R., Sause W. T., Livingston R. B., Komaki R., Wagner H., Aisner S., Johnson D. H. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999 Jan 28;340(4):265–271. doi: 10.1056/NEJM199901283400403. [DOI] [PubMed] [Google Scholar]
  64. Werner-Wasik M., Pequignot E., Leeper D., Hauck W., Curran W. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):689–696. doi: 10.1016/s0360-3016(00)00699-4. [DOI] [PubMed] [Google Scholar]
  65. Willett C., Ajani J., Kelsen D., Sigurdson E., Abrams R., Berkey B., Benetz M., Crane C., Gaspar L., Goodyear M. D. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys. 2001;51(3 Suppl 2):19–27. [PubMed] [Google Scholar]
  66. de Boer H. C., van Sörnsen de Koste J. R., Senan S., Visser A. G., Heijmen B. J. Analysis and reduction of 3D systematic and random setup errors during the simulation and treatment of lung cancer patients with CT-based external beam radiotherapy dose planning. Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):857–868. doi: 10.1016/s0360-3016(00)01413-9. [DOI] [PubMed] [Google Scholar]
  67. van Sörnsen de Koste J. R., Lagerwaard F. J., Schuchhard-Schipper R. H., Nijssen-Visser M. R., Voet P. W., Oei S. S., Senan S. Dosimetric consequences of tumor mobility in radiotherapy of stage I non-small cell lung cancer--an analysis of data generated using 'slow' CT scans. Radiother Oncol. 2001 Oct;61(1):93–99. doi: 10.1016/s0167-8140(01)00373-5. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES